This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

11 Mar 2013

Apposition III clinical trials show low mortality rates

The Stentys Self-Apposing Stent clinical trials show low death rates in patients following severe heart attack.

Clinical trials into Stentys Self-Apposing Stent have shown positive outcomes after one year.
The firm released its 12-month results for the Apposition III clinical trials, which tested the stent in treatment of 1000 patients who had suffered a severe heart attack.

Apposition III assessed the long-term outcomes of Stentus Self-Apposing Stent in routine clinical practice among people who had suffered an ST-elevation myocardial infarction.

While conventional stents resulted in a 2.2%-3.9% mortality rate at the one-year point, Stentys's product showed a cardiac death rate of 2%.

Clinical trial investigator Professor Gilles Montalescot told the American College of Cariology's Scientific Session & Expo: "The very low rates of mortality (2.0%) and target-vessel re-infarction (1.3%) in the APPOSITION III study clearly highlight the excellent safety profile of Self-Apposing stents."

A stent treats narrow and weak arteries, constructed of either metal or fabric mesh, in order to reduce the risk of repeated closure or blockage.

Related News